Related references
Note: Only part of the references are listed.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Inclisiran-New hope in the management of lipid disorders?
Krzysztof Dyrbus et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition
Arturo Cesaro et al.
BIOFACTORS (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Lipoprotein(a) plasma levels are not associated with survival after acute coronary syndromes: An observational cohort study
Christian Roth et al.
PLOS ONE (2020)
INCLISIRAN AND CARDIOVASCULAR OUTCOMES: ANALYSES FROM ORION-11
Kausik Kumar Ray et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Screening for High Lipoprotein(a) The Time Is Now
George Thanassoulis
CIRCULATION (2019)
Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents
C. Macchi et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2019)
Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes
Baris Gencer et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2019)
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease
Felice Gragnano et al.
INTERNAL AND EMERGENCY MEDICINE (2019)
Impact of PCSK9 inhibitors on plasma lipoprotein (a) concentrations with or without a background of niacin therapy
Bruce A. Warden et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
Kausik K. Ray et al.
ATHEROSCLEROSIS (2019)
A new dawn for managing dyslipidemias: The era of ma-based therapies
C. Macchi et al.
PHARMACOLOGICAL RESEARCH (2019)
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives
M. F. Wu et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis
Reinhard Klingel et al.
ATHEROSCLEROSIS SUPPLEMENTS (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Daniel F. Gudbjartsson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
High levels of lipoprotein (a) and premature acute coronary syndrome
Loukianos S. Rallidis et al.
ATHEROSCLEROSIS (2018)
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins Prespecified Secondary End Points in ORION 1
Kausik K. Ray et al.
CIRCULATION (2018)
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
Gerald F. Watts et al.
EUROPEAN HEART JOURNAL (2018)
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting
Rutger Verbeek et al.
EUROPEAN HEART JOURNAL (2018)
Relationship between LDL-C, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide
Nicholas J. Viney et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Gissette Reyes-Soffer et al.
CIRCULATION (2017)
Lipoprotein(a): the revenant
Baris Gencer et al.
EUROPEAN HEART JOURNAL (2017)
The metabolism of lipoprotein (a): an ever-evolving story
Gissette Reyes-Soffer et al.
JOURNAL OF LIPID RESEARCH (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity
S. N. Pokrovsky et al.
ATHEROSCLEROSIS SUPPLEMENTS (2017)
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2016)
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Eli M. Roth et al.
ATHEROSCLEROSIS (2016)
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
Michel Farnier et al.
ATHEROSCLEROSIS (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Structure, function, and genetics of lipoprotein (a)
Konrad Schmidt et al.
JOURNAL OF LIPID RESEARCH (2016)
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
Frederick J. Raal et al.
JOURNAL OF LIPID RESEARCH (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
The relationship between Lp(a) and CVD outcomes: a systematic review
Carol A. Forbes et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Dean J. Kereiakes et al.
AMERICAN HEART JOURNAL (2015)
Impact of Lipoprotein(a) as Residual Risk on Long-Term Outcomes in Patients After Percutaneous Coronary Intervention
Hirokazu Konishi et al.
AMERICAN JOURNAL OF CARDIOLOGY (2015)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Christopher P. Cannon et al.
EUROPEAN HEART JOURNAL (2015)
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Harold Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Sotirios Tsimikas et al.
LANCET (2015)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial
Eli M. Roth et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik Stroes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Anti-PCSK9 Monotherapy for Hypercholesterolemia The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab
Michael J. Koren et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Frederick J. Raal et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lipoprotein(a): resurrected by genetics
F. Kronenberg et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Lipoprotein(a) metabolism: Potential sites for therapeutic targets
Jane Hoover-Plow et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
History of Discovery Oxidized Low-Density Lipoprotein and Atherosclerosis
Daniel Steinberg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
Eric Bruckert et al.
ATHEROSCLEROSIS (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
The Mysteries of Lipoprotein(a) and Cardiovascular Disease Revisited
Stefan Kiechl et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Lipoprotein a: where are we now?
Konstantinos Tziomalos et al.
CURRENT OPINION IN CARDIOLOGY (2009)
Mechanism of action of niacin
Vaijinath S. Kamanna et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and apoB-containing lipoproteins
Stefania Lamon-Fava et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population
Pia R. Kamstrup et al.
CIRCULATION (2008)
Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity
ML Koschinsky et al.
CURRENT OPINION IN LIPIDOLOGY (2004)
Share Paper
